MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Intra-Cellular Therapies Inc

Closed

SectorHealthcare

131.89 -0.02

Overview

Share price change

24h

Current

Min

131.89

Max

131.89

Key metrics

By Trading Economics

Income

9.4M

-17M

Sales

24M

199M

EPS

-0.16

Profit margin

-8.475

Employees

860

EBITDA

9.8M

-29M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

-0.79% downside

Dividends

By Dow Jones

Next Earnings

6 maj 2025

Market Stats

By TradingEconomics

Market Cap

1.8B

14B

Previous open

131.91

Previous close

131.89

News Sentiment

By Acuity

51%

49%

320 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Intra-Cellular Therapies Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 sty 2025, 12:11 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson to Acquire Intra-Cellular in $14.6 Billion Deal

13 sty 2025, 11:40 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson in Talks to Acquire Intra-Cellular Therapies, Says Bloomberg

14 mar 2025, 09:30 UTC

Top News

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

22 sty 2025, 14:09 UTC

Top News
Earnings

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

22 sty 2025, 11:22 UTC

Top News
Earnings

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

13 sty 2025, 21:20 UTC

Acquisitions, Mergers, Takeovers

J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug -- IBD

13 sty 2025, 20:12 UTC

Top News
Acquisitions, Mergers, Takeovers

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal -- Update

13 sty 2025, 16:18 UTC

Top News
Acquisitions, Mergers, Takeovers

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal -- WSJ

13 sty 2025, 15:57 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Bets Big on Mental Health Drugs With $14.6 Billion Intra-Cellular Deal -- Barrons.com

13 sty 2025, 14:10 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal -- IBD

13 sty 2025, 12:25 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson in $14.6 Billion Deal to Buy Biotech Intra-Cellular -- Barrons.com

13 sty 2025, 11:57 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Confirms $14.6 Billion Deal to Buy Biotech Intra-Cellular -- Barrons.com

13 sty 2025, 11:56 UTC

Top News
Acquisitions, Mergers, Takeovers

Johnson & Johnson to Acquire Intra-Cellular in $14.6B Deal

13 sty 2025, 11:45 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: Intra-Cellular's Clinical-Stage Pipeline Has Best-In-Disease Potential in Generalized Anxiety Disorder, Alzheimer's Treatments >JNJ

13 sty 2025, 11:43 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: Caplyta Solidifies Sales Above Analyst Expectations Through Remainder of Decade>JNJ

13 sty 2025, 11:43 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: Caplyta Has Potential of Over $5 Billion in Peak Yr Sales >JNJ

13 sty 2025, 11:42 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Purchases Intra-Cellular for $132/Shr in Cash, or About $14.6B >JNJ

13 sty 2025, 11:41 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: SNDA Submitted to FDA for Caplyta as Adjunctive Treatment for Major Depressive Disorder >JNJ

13 sty 2025, 11:40 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: Acquisition Includes CaplytaTreatment for Bipolar I and II Depression, Schizophrenia >JNJ

13 sty 2025, 11:34 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: Deal Adds Intra-Cellular's Caplyta Depression Drug >JNJ ITCI

13 sty 2025, 11:32 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: To Maintain Strong Balance Sheet, Continue to Support Capital-Allocation Priorities >JNJ

13 sty 2025, 11:32 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson To Fund Transaction With Cash on Hand, Debt >JNJ ITCI

13 sty 2025, 11:31 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson to Buy Intra-Cellular Therapies for About $14.6 Billion >JNJ ITCI

13 sty 2025, 11:31 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson to Buy Intra-Cellular Therapies for $132/Share in Cash >JNJ ITCI

13 sty 2025, 11:30 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Strengthens Neuroscience Leadership With Acquisition Of Intra-Cellular Therapies, Inc. >JNJ ITCI

13 sty 2025, 10:55 UTC

Acquisitions, Mergers, Takeovers

This Stock Is Soaring Amid Johnson & Johnson Takeover Report -- Barrons.com

13 sty 2025, 10:41 UTC

Acquisitions, Mergers, Takeovers

This Stock Is Soaring Amid J&J Takeover Report. What to Know. -- Barrons.com

Peer Comparison

Price change

Intra-Cellular Therapies Inc Forecast

Price Target

By TipRanks

-0.79% downside

12 Months Forecast

Average 130.83 USD  -0.79%

High 132 USD

Low 118 USD

Based on 13 Wall Street analysts offering 12 month price targets forIntra-Cellular Therapies Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

13 ratings

4

Buy

9

Hold

0

Sell

Technical Score

By Trading Central

131.45 / 131.87Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

No Evidence

Long Term

No Evidence

Sentiment

By Acuity

320 / 386 Ranking in Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Intra-Cellular Therapies Inc

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.